VSTM - Verastem, Inc.
IEX Last Trade
3.95
0.070 1.772%
Share volume: 42,703
Last Updated: Thu 26 Dec 2024 08:29:53 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$3.88
0.07
1.80%
Fundamental analysis
23%
Profitability
25%
Dept financing
14%
Liquidity
75%
Performance
10%
Performance
5 Days
-1.52%
1 Month
-3.70%
3 Months
49.43%
6 Months
27.04%
1 Year
-51.49%
2 Year
1,040.35%
Key data
Stock price
$3.95
DAY RANGE
$3.82 - $4.26
52 WEEK RANGE
$2.28 - $14.22
52 WEEK CHANGE
-$52.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Brian M. Stuglik
Region: US
Website: verastem.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: verastem.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Recent news